Many high-value therapeutic targets remain difficult to drug, particularly where targets are intracellular, conformationally complex, poorly accessible, highly conserved or embedded in membrane environments. Traditional discovery approaches can struggle in these settings, especially when target presentation, biological context or immune response variability limits the quality of the resulting binders.
In the full article, Isogenica explores how VHH single-domain antibodies could help expand the addressable target space for next-generation therapeutics. VHHs are small, stable and highly engineerable, giving them potential advantages in accessing hidden epitopes, supporting intracellular applications as intrabodies, and enabling new discovery strategies for targets that have historically been considered difficult or “undruggable.”
The blog also looks at how advances in membrane protein solubilisation, allosteric modulation and therapeutic delivery technologies are changing what is possible in drug discovery. For biotech and biopharma teams working on complex biology, it highlights why VHH discovery may offer a flexible route to novel binders where conventional antibody formats or small molecules may be limited.
Read the full blog:
https://isogenica.com/hard-to-drug-targets-vhh-antibodies/